

| L Number | Hits | Search Text | DB | Time stamp |
|----------|------|--------------------------|---|------------------|
| 1 | 173 | corte.inv. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/08/17 14:42 |
| 2 | 2277 | bart.inv. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/08/17 14:42 |
| 3 | 21 | corte.inv. adj bart.inv. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/08/17 15:36 |
| 4 | 838 | (544/321).CCLS. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/08/17 15:37 |
| 5 | 469 | (514/272).CCLS. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/08/17 15:37 |

| L Number | Hits | Search Text | DB | Time stamp |
|----------|------|--------------------------|---|------------------|
| 1 | 173 | corte.inv. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/08/17 14:42 |
| 2 | 2277 | bart.inv. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/08/17 14:42 |
| 3 | 21 | corte.inv. adj bart.inv. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/08/17 15:36 |
| 4 | 838 | (544/321).CCLS. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/08/17 15:37 |
| 5 | 469 | (514/272).CCLS. | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/08/17 15:37 |

V. Balasubramanian

Welcome to STN International! Enter x:x

LOGINID:sssptal61lbxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

| | | | |
|--------------|----|---------|---|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | May 12 | EXTEND option available in structure searching |
| NEWS | 4 | May 12 | Polymer links for the POLYLINK command completed in REGISTRY |
| NEWS | 5 | May 27 | New UPM (Update Code Maximum) field for more efficient patent SDIs in CPlus |
| NEWS | 6 | May 27 | CPlus super roles and document types searchable in REGISTRY |
| NEWS | 7 | Jun 28 | Additional enzyme-catalyzed reactions added to CASREACT |
| NEWS | 8 | Jun 28 | ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R) |
| NEWS | 9 | Jul 12 | BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS |
| NEWS | 10 | Jul 30 | BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting |
| NEWS | 11 | AUG 02 | IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields |
| NEWS | 12 | AUG 02 | CPlus and CA patent records enhanced with European and Japan Patent Office Classifications |
| NEWS | 13 | AUG 02 | STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting |
| NEWS | 14 | AUG 02 | The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available |
| NEWS | 15 | AUG 04 | Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004 |
| NEWS EXPRESS | | JULY 30 | CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004 |
| NEWS HOURS | | | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | | | General Internet Information |
| NEWS LOGIN | | | Welcome Banner and News Items |
| NEWS PHONE | | | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | | | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

V. Balasubramanian

FILE 'HOME' ENTERED AT 14:20:42 ON 17 AUG 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:20:57 ON 17 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 AUG 2004 HIGHEST RN 727651-15-2

DICTIONARY FILE UPDATES: 16 AUG 2004 HIGHEST RN 727651-15-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.


Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>Testing the current file..... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\STNEXP4\QUERIES\10634682.str



chain nodes :

7 9 21 22

ring nodes :

1 2 3 4 5 6 8 10 11 12 13 14 15 16 17 18 19 20

chain bonds :

3-9 5-7 7-8 9-10

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-16 8-20 10-11 10-15 11-12 12-13 13-14 14-15
16-17 17-18 18-19 19-20

exact/norm bonds :

3-9 5-7 7-8 9-10

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-16 8-20 10-11 10-15 11-12 12-13 13-14 14-15
16-17 17-18 18-19 19-20

10/634,682

V. Balasubramanian

isolated ring systems :
containing 1 : 8 : 10 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 22:CLASS 23:CLASS 24:CLASS

L1 STRUCTURE UPLOADED


=> que L1

L2 QUE L1

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:21:20 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 4 TO 200


PROJECTED ANSWERS: 3 TO 163

L3 3 SEA SSS SAM L1

=> d scan

V. Balasubramanian

L3 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Benzonitrile, 3,5-dibromo-4-[[2-[(4-cyanophenyl)amino]-5-fluoro-6-(hydroxymethyl)-4-pyrimidinyl]oxy]- (9CI)
MF C19 H10 Br2 F N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

V. Balasubramanian

L3 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN

IN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-

MF C20 H14 Br N5 O




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

V. Balasubramanian

L3 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN

IN Acetamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)- (9CI)

MF C22 H16 Br N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

V. Balasubramanian

=> s l1 sss ful

FULL SEARCH INITIATED 14:21:41 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 79 TO ITERATE

100.0% PROCESSED 79 ITERATIONS

51 ANSWERS

SEARCH TIME: 00.00.01

L4 51 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.42

155.63

FILE 'CAPLUS' ENTERED AT 14:21:46 ON 17 AUG 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Aug 2004 VOL 141 ISS 8

FILE LAST UPDATED: 16 Aug 2004 (20040816/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l4

L5 23 L4


=> d l5 1-23 bib hitstr

V. Balasubramanian

L5 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:486399 CAPLUS
DN 141:54353
TI Pharmaceutical compositions comprising a surfactant and a physiologically tolerable water-soluble acid respectively base, and a basic respectively acidic drug compound, containing a pyrimidine unit, for treating HIV
IN Vandecruys, Roger Petrus Gerebern
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004050068 | A1 | 20040617 | WO 2002-EP13558 | 20021129 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | WO 2004050058 | A2 | 20040617 | WO 2003-EP50890 | 20031125 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| PRAI | WO 2002-EP13558 | A | 20021129 | | |
| IT | 269055-15-4P | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (anti-HIV agent; preparation of pyrimidine-based anti-HIV agents and their pharmaceutical compns.) | | | | |
| RN | 269055-15-4 CAPLUS | | | | |
| CN | Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME) | | | | |

V. Balasubramanian



RE.CNT 10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:412943 CAPLUS

DN 140:423711

TI Preparation of 1,1-dioxido-4H-1,2,4-benzothiadiazines as hepatitis C polymerase inhibitors and anti-infective agents

IN Pratt, John K.; Betebenner, David A.; Donner, Pamela L.; Green, Brian E.; Kempf, Dale J.; McDaniel, Keith F.; Maring, Clarence J.; Stoll, Vincent S.; Zhang, Rong

PA Abbott Laboratories, USA

SO PCT Int. Appl., 514 pp.


CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004041818 | A1 | 20040521 | WO 2003-US34707 | 20031031 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU | | | | |
| | RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2004097492 | A1 | 20040520 | US 2002-285714 | 20021101 |
| | US 2004087577 | A1 | 20040506 | US 2003-410853 | 20030410 |
| PRAI | US 2002-285714 | A | 20021101 | | |
| | US 2003-410853 | A | 20030410 | | |
| | US 2003-625121 | A | 20030723 | | |
| | US 2003-679881 | A | 20031006 | | |
| OS | MARPAT 140:423711 | | | | |
| IT | 269055-15-4, TMC-125 | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination therapy; preparation of 1,1-dioxidobenzothiadiazines as hepatitis C polymerase inhibitors and anti-infective agents) | | | | |
| RN | 269055-15-4 CAPLUS | | | | |
| CN | Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME) | | | | |




V. Balasubramanian

L5 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:279153 CAPLUS
DN 141:406
TI Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (Etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants
AU Das, Kalyan; Clark, Arthur D., Jr.; Lewi, Paul J.; Heeres, Jan; De Jonge, Marc R.; Koymans, Lucien M. H.; Vinkers, H. Maarten; Daeyaert, Frederik; Ludovici, Donald W.; Kukla, Michael J.; De Corte, Bart; Kavash, Robert W.; Ho, Chih Y.; Ye, Hong; Lichtenstein, Mark. A.; Andries, Koen; Pauwels, Rudi; De Bethune, Marie-Pierre; Boyer, Paul L.; Clark, Patrick; Hughes, Stephen H.; Janssen, Paul A. J.; Arnold, Eddy
CS Center for Advanced Biotechnology and Medicine and Department of Chemistry and Chemical Biology, Rutgers University, Piscataway, NJ, 08854, USA
SO Journal of Medicinal Chemistry (2004), 47(10), 2550-2560
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
IT 269055-15-4, Etravirine 373686-05-6, R 185545
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(structure activity relationship of conformational and positional adaptability of non-nucleoside reverse transcriptase inhibitors against wild-type and drug-resistant HIV-1 variants)
RN 269055-15-4 CAPLUS
CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 373686-05-6 CAPLUS
CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-(hydroxymethyl)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)

V. Balasubramanian




RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:120835 CAPLUS
DN 140:163887
TI preparation of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinone
derivatives as HIV reverse transcriptase inhibitors
IN Corbett, Jeffrey
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2004013110 | A1 | 20040212 | WO 2003-US24006 | 20030731 |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU | | | | |
| | RW: | | | | |
| | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2004063734 | A1 | 20040401 | US 2003-632192 | 20030731 |
| PRAI | US 2002-400409P | P | 20020801 | | |
| OS | MARPAT 140:163887 | | | | |
| IT | 269055-15-4P, TMC-125 | | | | |
| | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinone derivs. as HIV reverse transcriptase inhibitors) | | | | |
| RN | 269055-15-4 CAPLUS | | | | |
| CN | Benzonitrile, 4-[[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME) | | | | |



V. Balasubramanian


L5 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:20432 CAPLUS
DN 140:77032
TI Preparation of 2,4-disubstituted pyridine N-oxides useful as HIV reverse transcriptase inhibitors
IN Rodgers, James D.; Wang, Haisheng
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2004002410 | A2 | 20040108 | WO 2003-US19917 | 20030625 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2004019047 | A1 | 20040129 | US 2003-603431 | 20030625 |
| PRAI | US 2002-392092P | P | 20020627 | | |
| OS | MARPAT 140:77032 | | | | |
| IT | 269055-15-4, TMC 125 | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (treatment in combination with; preparation of disubstituted pyridine N-oxides useful as HIV reverse transcriptase inhibitors) | | | | |
| RN | 269055-15-4 CAPLUS | | | | |
| CN | Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME) | | | | |



V. Balasubramanian


L5 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:986852 CAPLUS
DN 141:116472
TI TMC125 exerts similar initial antiviral potency as a five-drug, triple
class antiretroviral regimen
AU Sankatsing, Sanjay U.; Weverling, Gerrit J.; Peeters, Monika; van't
Klooster, Gerben A.; Gruzdev, Boris; Rakhmanova, Aza; Danner, Sven A.;
Jurriaans, Suzanne; Prins, Jan M.; Lange, Joep M.
CS Department of Internal Medicine, Division of Infectious Diseases, Tropical
Medicine and AIDS, Univ. Amsterdam, Amsterdam, Neth.
SO AIDS (London, United Kingdom) (2003), 17(18), 2623-2627
CODEN: AIDSET; ISSN: 0269-9370
PB Lippincott Williams & Wilkins
DT Journal
LA English
IT 269055-15-4, TMC-125
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(TMC125 exerts similar initial antiviral potency as a five-drug, triple
class antiretroviral regimen)
RN 269055-15-4 CAPLUS
CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-
pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:986848 CAPLUS
DN 141:116470
TI An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance
AU Gazzard, Brian G.; Pozniak, Anton L.; Rosenbaum, Willy; Yeni, G. Patrick; Staszewski, Schlomo; Arasteh, Keikawus; De Dier, Karin; Peeters, Monika; Woodfall, Brian; Stebbing, Justin; van't Klooster, Gerben A.
CS Chelsea and Westminster Hospital, London, UK
SO AIDS (London, United Kingdom) (2003), 17(18), F49-F54
CODEN: AIDSET; ISSN: 0269-9370
PB Lippincott Williams & Wilkins
DT Journal
LA English
IT **269055-15-4**, TMC 125
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(new generation NNRTI TMC-125 is well tolerated with significant antiviral activity in HIV-1 patient even in presence of mutations conferring high level of phenotypic resistance to efavirenz and nevirapine)
RN 269055-15-4 CAPLUS
CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:913004 CAPLUS
DN 139:374987
TI Microbicidal pyrimidine or triazine compounds for preventing sexual HIV transmission
IN Van Roey, Jens Marcel; De Bethune, Marie-Pierre T. M. M. G.; Stoffels, Paul
PA Tibotec Pharmaceuticals Ltd., Ire.
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|----------|
| PI | WO 2003094920 | A1 | 20031120 | WO 2003-EP50158 | 20030513 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |


PRAI EP 2002-76897 A 20020513

OS MARPAT 139:374987

IT 244767-99-5 244767-99-5D, N-oxide or quaternary amine derivs. 269055-04-1 269055-04-1D, N-oxide or quaternary amine derivs. 269055-15-4 269055-15-4D, N-oxide or quaternary amine derivs. 269055-19-8 269055-19-8D, N-oxide or quaternary amine derivs.
RL: DEV (Device component use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyrimidine and triazine compds. for preventing sexual HIV transmission)

RN 244767-99-5 CAPLUS


CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-
(9CI) (CA INDEX NAME)



V. Balasubramanian


RN 244767-99-5 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-
(9CI) (CA INDEX NAME)



RN 269055-04-1 CAPLUS


CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-04-1 CAPLUS


CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 269055-15-4 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-15-4 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




10/634,682

V. Balasubramanian


RN 269055-19-8 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-19-8 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RE.CNT 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:892834 CAPLUS
DN 139:365764
TI Diblock copolymers for use in pharmaceutical dosage forms
IN Arieen, Albertina Maria Eduarda; Brewster, Marcus Eli; Nathan, Aruna;
Rosenblatt, Joel; Ould-Ouali, Louisa Myriam; Preat, Veronique
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|--|----------|-----------------|----------|
| PI | WO 2003093344 | A1 | 20031113 | WO 2003-EP4368 | 20030424 |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| PRAI | US 2002-377901P | P | 20020503 | | |
| IT | 269055-15-4, TMC 125 | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) | | | | |
| | (diblock copolymers for use in pharmaceutical dosage forms) | | | | |
| RN | 269055-15-4 CAPLUS | | | | |
| CN | Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME) | | | | |



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:871684 CAPLUS
DN 141:99044
TI A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day
monotherapy in antiretroviral naive, HIV-1 infected subjects
AU Gruzdev, Boris; Rakhmanova, Aza; Doubovskaya, Ekaterina; Yakovlev, Alexey;
Peeters, Monika; Rinehart, Alex; De Dier, Karin; Baede-Van Dijk, Patricia;
Parys, Wim; Van't Klooster, Gerben
CS Infectious Diseases Hospital, Russian Federation, Neth.
SO AIDS (London, United Kingdom) (2003), 17(17), 2487-2494
CODEN: AIDSET; ISSN: 0269-9370
PB Lippincott Williams & Wilkins
DT Journal
LA English
IT 269055-15-4, TMC125
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological
study); USES (Uses)
(short-term TMC125 monotherapy was well tolerated with steady-state
pharmacokinetics, decreased plasma HIV-1 RNA with remarkable viral
decay rate and increased CD4 cell count in antiretroviral naive, HIV-1
infected patients)
RN 269055-15-4 CAPLUS
CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-
pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:591181 CAPLUS
DN 139:149647
TI Preparation of 5,10-dihydropyrimido[5,4-b]quinolin-4(3H)-ones as HIV
reverse transcriptase inhibitors
IN Tarby, Christine M.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2003062238 | A1 | 20030731 | WO 2003-US1604 | 20030116 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2003162800 | A1 | 20030828 | US 2003-346613 | 20030117 |
| PRAI | US 2002-349641P | P | 20020118 | | |
| OS | MARPAT 139:149647 | | | | |
| IT | 269055-15-4, TMC 125 | | | | |
| | RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination therapy; preparation of pyrimido[5,4-b]quinolinones as HIV reverse transcriptase inhibitors) | | | | |
| RN | 269055-15-4 CAPLUS | | | | |
| CN | Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME) | | | | |



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian


L5 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:316300 CAPLUS
DN 139:46478
TI Validation of a model for the complex of HIV-1 reverse transcriptase with
nonnucleoside inhibitor TMC125
AU Udier-Blagovic, Marina; Tirado-Rives, Julian; Jorgensen, William L.
CS Department of Chemistry, Yale University, New Haven, CT, 06520-8107, USA
SO Journal of the American Chemical Society (2003), 125(20), 6016-6017
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
IT 269055-15-4, TMC 125
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological
study)
(validation of a model for the complex of HIV-1 reverse transcriptase
with nonnucleoside inhibitor TMC125)
RN 269055-15-4 CAPLUS
CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-
pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:302361 CAPLUS
DN 139:345031
TI New antiretroviral drugs
AU Gulick, R. M.
CS Cornell HIV Clinical Trials Unit, Division of International Medicine and
Infectious Diseases, Weill Medical College of Cornell University, New
York, NY, 10024, USA
SO Clinical Microbiology and Infection (2003), 9(3), 186-193
CODEN: CMINFM; ISSN: 1198-743X
PB Blackwell Publishing Ltd.
DT Journal; General Review
LA English
IT 269055-15-4, TMC 125
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(new antiretroviral drugs)
RN 269055-15-4 CAPLUS
CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-
pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:695941 CAPLUS

DN 137:232453

TI Preparation of substituted benzophenones as inhibitors of reverse transcriptase

IN Chan, Joseph Howing

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 163 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2002070470 | A2 | 20020912 | WO 2002-US6037 | 20020228 |
| | WO 2002070470 | A3 | 20030306 | | |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: | | | | |
| | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP | 1363877 | A2 | 20031126 | EP 2002-723265 | 20020228 |
| | R: | | | | |
| | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR | 2002007752 | A | 20040323 | BR 2002-7752 | 20020228 |
| NZ | 527864 | A | 20040528 | NZ 2002-527864 | 20020228 |
| NO | 2003003857 | A | 20031027 | NO 2003-3857 | 20030901 |
| US | 2004122064 | A1 | 20040624 | US 2004-469104 | 20040205 |
| PRAI | US 2001-272953P | P | 20010302 | | |
| | WO 2002-US6037 | W | 20020228 | | |


OS MARPAT 137:232453

IT 269055-15-4, TMC-125

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of substituted benzophenones as inhibitors of reverse transcriptase)

RN 269055-15-4 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



V. Balasubramanian

L5 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:90044 CAPLUS

DN 136:151150

TI Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors and their use as antiviral agents in the treatment of HIV infection

IN Rodgers, James D.; Wang, Haisheng; Patel, Mona; Arvanitis, Argyrios; Cocuzza, Anthony J.

PA Dupont Pharmaceuticals Company, USA

SO PCT Int. Appl., 189 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2002008226 | A2 | 20020131 | WO 2001-US22827 | 20010720 |
| | WO 2002008226 | A3 | 20020620 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | US 2002107261 | A1 | 20020808 | US 2001-908995 | 20010719 |
| | US 6596729 | B2 | 20030722 | | |
| | EP 1303515 | A2 | 20030423 | EP 2001-959047 | 20010720 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| | SI 21139 | C | 20030831 | SI 2001-20050 | 20010720 |
| | BG 107439 | A | 20030930 | BG 2003-107439 | 20030106 |
| | NO 2003000248 | A | 20030317 | NO 2003-248 | 20030117 |
| | US 2004023955 | A1 | 20040205 | US 2003-457902 | 20030610 |
| PRAI | US 2000-219532P | P | 20000720 | | |
| | US 2001-284856P | P | 20010419 | | |
| | US 2001-908995 | A3 | 20010719 | | |
| | WO 2001-US22827 | W | 20010720 | | |

OS MARPAT 136:151150


IT 269055-15-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. also containing; preparation of tricyclic 2-pyridone compds. as HIV reverse transcriptase inhibitors)

RN 269055-15-4 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)

V. Balasubramanian



V. Balasubramanian

L5 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:833290 CAPLUS
DN 135:371765
TI Preparation of substituted amino pyrimidines and triazines as HIV
replication inhibitors
IN Kukla, Michael Joseph; Ludovici, Donald William; Kavash, Robert W.; De
Corte, Bart Lieven Daniel; Heeres, Jan; Janssen, Paul Adriaan Jan;
Koymans, Lucien Maria Henricus; De Jonge, Marc Rene; Van Aken Koen, Jeanne
Alfons; Krief, Alain; Leenders, Ruben Gerardus George
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-----------------|--|----------|-----------------|----------|
| PI | WO 2001085700 | A2 | 20011115 | WO 2001-EP4991 | 20010503 |
| | WO 2001085700 | A3 | 20020207 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | EP 1282606 | A2 | 20030212 | EP 2001-929616 | 20010503 |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | |
| | JP 2003535828 | T2 | 20031202 | JP 2001-582301 | 20010503 |
| | US 2003171374 | A1 | 20030911 | US 2002-275931 | 20021108 |
| PRAI | US 2000-202472P | P | 20000508 | | |
| | WO 2001-EP4991 | W | 20010503 | | |

OS MARPAT 135:371765


IT **373684-83-4P 373688-31-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted amino pyrimidines and triazines as HIV replication inhibitors)

RN 373684-83-4 CAPLUS


CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-6-(methoxymethyl)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 373688-31-4 CAPLUS

CN Benzonitrile, 3,5-dibromo-4-[[2-[(4-cyanophenyl)amino]-6-(hydroxymethyl)-4-pyrimidinyl]oxy]- (9CI) (CA INDEX NAME)




IT 373684-45-8P 373686-00-1P 373686-05-6P
373686-12-5P 373686-18-1P 373686-25-0P
373686-31-8P 373688-25-6P 373689-13-5P
373689-18-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted amino pyrimidines and triazines as HIV replication inhibitors)

RN 373684-45-8 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 6-(4-cyano-2,6-dimethylphenoxy)-2-[(4-cyanophenyl)amino]-, methyl ester (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 373686-00-1 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-(methoxymethyl)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 373686-05-6 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-(hydroxymethyl)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




10/634,682

V. Balasubramanian


RN 373686-12-5 CAPLUS

CN Benzonitrile, 4-[[5-bromo-6-(chloromethyl)-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 373686-18-1 CAPLUS


CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-[(methylamino)methyl]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 373686-25-0 CAPLUS


CN Benzonitrile, 3,5-dibromo-4-[[2-[(4-cyanophenyl)amino]-5-fluoro-6-(hydroxymethyl)-4-pyrimidinyl]oxy]- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 373686-31-8 CAPLUS

CN Benzonitrile, 3,5-dibromo-4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-(hydroxymethyl)-4-pyrimidinyl]oxy]- (9CI) (CA INDEX NAME)



RN 373688-25-6 CAPLUS

CN Benzonitrile, 3,5-dibromo-4-[[2-[(4-cyanophenyl)amino]-6-(methoxymethyl)-4-pyrimidinyl]oxy]- (9CI) (CA INDEX NAME)




10/634,682

V. Balasubramanian


RN 373689-13-5 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-[(dimethylamino)methyl]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 373689-18-0 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-[(ethylamino)methyl]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)





V. Balasubramanian

L5 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:833289 CAPLUS
DN 135:371756
TI Preparation of prodrugs of HIV replication inhibiting pyrimidines
IN Kukla, Michael Joseph; Ludovici, Donald William; Kavash, Robert W.; De
Corte, Bart Lieven Daniel; Heeres, Jan; Janssen, Paul Adriaan Jan;
Koymans, Lucien Maria Henricus; De Jonge, Marc Rene; Van Aken Koen, Jeanne
Alfons; Krief, Alain
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1



| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|--|------|----------|-----------------|----------|
| PI | WO 2001085699 | A2 | 20011115 | WO 2001-EP4990 | 20010503 |
| | WO 2001085699 | A3 | 20020228 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 2001060277 | A5 | 20011120 | AU 2001-60277 | 20010503 |
| | EP 1282607 | A2 | 20030212 | EP 2001-933925 | 20010503 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | JP 2003532713 | T2 | 20031105 | JP 2001-582300 | 20010503 |
| | US 2003186990 | A1 | 20031002 | US 2002-275333 | 20021107 |
| PRAI | US 2000-202471P | P | 20000508 | | |
| | WO 2001-EP4990 | W | 20010503 | | |
| OS | MARPAT 135:371756 | | | | |
| IT | 373791-74-3P 373791-80-1P 373791-86-7P 373791-91-4P 373791-97-0P 373792-02-0P 373792-10-0P 373792-16-6P 373792-24-6P 373792-32-6P 373792-37-1P 373792-43-9P 373792-48-4P 373792-54-2P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of prodrugs of HIV replication inhibiting pyrimidines) | | | | |
| RN | 373791-74-3 CAPLUS | | | | |
| CN | Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)(ethoxymethyl)amino]-4- pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME) | | | | |

V. Balasubramanian




RN 373791-80-1 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(cyanomethyl)(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 373791-86-7 CAPLUS


CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)[(2-hydroxyethoxy)methyl]amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 373791-91-4 CAPLUS


CN Butanoic acid, 4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl](4-cyanophenyl)amino]-4-oxo-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 373791-97-0 CAPLUS

CN Benzonitrile, 4-[[2-[[[2-(benzoyloxy)ethoxy]methyl](4-cyanophenyl)amino]-5-bromo-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 373792-02-0 CAPLUS


CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)[(octyloxy)methyl]amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 373792-10-0 CAPLUS


CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)[(2-methoxyethoxy)methyl]amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 373792-16-6 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)-1-methyl- (9CI) (CA INDEX NAME)




RN 373792-24-6 CAPLUS

CN Methanesulfonamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 373792-32-6 CAPLUS


CN Benzenesulfonamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 373792-37-1 CAPLUS

CN Benzenesulfonamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 373792-43-9 CAPLUS

CN Octanamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)




RN 373792-48-4 CAPLUS

CN Butanoic acid, 4-[[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl](4-cyanophenyl)amino]-4-oxo-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 373792-54-2 CAPLUS

CN Butanoic acid, 4-[[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl](4-cyanophenyl)amino]-4-oxo-, 2-[[2-(dimethylamino)ethyl]methylamino]ethyl ester (9CI) (CA INDEX NAME)




IT 269055-76-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of prodrugs of HIV replication inhibiting pyrimidines)

RN 269055-76-7 CAPLUS

CN Benzonitrile, 4-[[5-bromo-6-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



IT 269055-04-1P 269055-15-4P 269055-19-8P

269055-42-7P 269055-44-9P 269055-48-3P

269055-49-4P 269055-50-7P 269055-51-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of prodrugs of HIV replication inhibiting pyrimidines)

RN 269055-04-1 CAPLUS


CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 269055-15-4 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-19-8 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




10/634,682

V. Balasubramanian


RN 269055-42-7 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-nitro-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-44-9 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-methyl-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-48-3 CAPLUS


CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 269055-49-4 CAPLUS


CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-(methoxyamino)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-50-7 CAPLUS


CN Acetamide, N-[4-(4-cyano-2,6-dimethylphenoxy)-2-[(4-cyanophenyl)amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 269055-51-8 CAPLUS

CN Benzonitrile, 4-[[5-amino-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




V. Balasubramanian

L5 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:628977 CAPLUS
DN 135:371702
TI Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues
AU Ludovici, D. W.; De Corte, B. L.; Kukla, M. J.; Ye, H.; Ho, C. Y.; Lichtenstein, M. A.; Kavash, R. W.; Andries, K.; de Bethune, M.-P.; Azijn, H.; Pauwels, R.; Lewi, P. J.; Heeres, J.; Koymans, L. M. H.; de Jonge, M. R.; Van Aken, K. J. A.; Daeyaert, F. F. D.; Das, K.; Arnold, E.; Janssen, P. A. J.
CS Janssen Research Foundation, Spring House, PA, 19477, USA
SO Bioorganic & Medicinal Chemistry Letters (2001), 11(17), 2235-2239
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
IT 244767-99-5P 269055-04-1P 269055-05-2P
269055-15-4P 269055-42-7P 269055-50-7P
269055-51-8P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (synthesis and activity of diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors)
RN 244767-99-5 CAPLUS
CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-04-1 CAPLUS
CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 269055-05-2 CAPLUS

CN Benzonitrile, 4-[[5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-15-4 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




10/634,682

V. Balasubramanian


RN 269055-42-7 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-nitro-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-50-7 CAPLUS


CN Acetamide, N-[4-(4-cyano-2,6-dimethylphenoxy)-2-[(4-cyanophenyl)amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 269055-51-8 CAPLUS

CN Benzonitrile, 4-[[5-amino-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)

V. Balasubramanian




RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian


L5 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:247156 CAPLUS
DN 134:280865
TI Preparation of azinylaminobenzonitriles and related compounds as
virucides.
IN Verreck, Geert; Baert, Lieven
PA Janssen Pharmaceutica N.V., Belg.
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-------------------|----------|
| PI | WO 2001022938 | A1 | 20010405 | WO 2000-EP8522 | 20000831 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | BR 2000014271 | A | 20020521 | BR 2000-14271 | 20000831 |
| | EP 1225874 | A1 | 20020731 | EP 2000-964080 | 20000831 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| | JP 2003510264 | T2 | 20030318 | JP 2001-526150 | 20000831 |
| | EE 200200151 | A | 20030415 | EE 2002-151 | 20000831 |
| | NZ 517025 | A | 20030725 | NZ 2000-517025 | 20000831 |
| | TR 200200763 | T2 | 20030922 | TR 2002-200200763 | 20000831 |
| | BG 106521 | A | 20021229 | BG 2002-106521 | 20020314 |
| | ZA 2002002289 | A | 20030620 | ZA 2002-2289 | 20020320 |
| | NO 2002001443 | A | 20020322 | NO 2002-1443 | 20020322 |
| PRAI | EP 1999-203128 | A | 19990924 | | |
| | WO 2000-EP8522 | W | 20000831 | | |
| OS | MARPAT 134:280865 | | | | |
| IT | 269055-42-7P 269055-51-8P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of azinylaminobenzonitriles and related compds. as virucides) | | | | |
| RN | 269055-42-7 CAPLUS | | | | |
| CN | Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-nitro-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME) | | | | |

V. Balasubramanian



RN 269055-51-8 CAPLUS
CN Benzonitrile, 4-[[5-amino-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




IT 269055-04-1P 269055-05-2P 269055-14-3P
269055-15-4P 269055-18-7P 269055-19-8P
269055-26-7P 269055-28-9P 269055-32-5P
269055-44-9P 269055-48-3P 269055-49-4P
269055-50-7P 269055-58-5P 269055-59-6P
269055-60-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azinylaminobenzonitriles and related compds. as virucides)


RN 269055-04-1 CAPLUS
CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 269055-05-2 CAPLUS

CN Benzonitrile, 4-[[5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-14-3 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-(methylamino)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




10/634,682

V. Balasubramanian


RN 269055-15-4 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-18-7 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-(ethylamino)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-19-8 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-26-7 CAPLUS

CN Benzonitrile, 4-[[5,6-dichloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-28-9 CAPLUS


CN Benzonitrile, 4-[[6-bromo-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 269055-32-5 CAPLUS

CN Acetamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)




RN 269055-44-9 CAPLUS

CN Benzonitrile, 4-[[[5-bromo-2-[(4-cyanophenyl)amino]-6-methyl-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-48-3 CAPLUS

CN Benzonitrile, 4-[[[5-bromo-2-[(4-cyanophenyl)amino]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 269055-49-4 CAPLUS
 CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-(methoxyamino)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-50-7 CAPLUS
 CN Acetamide, N-[4-(4-cyano-2,6-dimethylphenoxy)-2-[(4-cyanophenyl)amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 269055-58-5 CAPLUS

CN Glycine, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 269055-59-6 CAPLUS


CN Formamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 269055-60-9 CAPLUS

CN Carbamic acid, [5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl] (4-cyanophenyl)-, ethyl ester (9CI) (CA INDEX NAME)

V. Balasubramanian




IT 269055-76-7

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of azinylaminobenzonitriles and related compds. as virucides)

RN 269055-76-7 CAPLUS

CN Benzonitrile, 4-[[5-bromo-6-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:225202 CAPLUS

DN 134:256875

TI Controlled-release microparticle formulation for antiviral drugs

IN Hantke, Thomas; Rehbock, Bettina; Rosenberg, Joerg; Breitenbach, Joerg

PA Knoll A.-G. Chemische Fabriken, Germany

SO Ger. Offen., 16 pp.


CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|------------------|----------|
| PI | DE 19945982 | A1 | 20010329 | DE 1999-19945982 | 19990924 |
| | WO 2001023362 | A2 | 20010405 | WO 2000-EP9149 | 20000919 |
| | WO 2001023362 | A3 | 20011206 | | |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| | RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | EP 1214300 | A2 | 20020619 | EP 2000-964201 | 20000919 |
| | EP 1214300 | B1 | 20030903 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| | JP 2003518012 | T2 | 20030603 | JP 2001-526516 | 20000919 |
| | AT 248822 | E | 20030915 | AT 2000-964201 | 20000919 |
| | NO 2002001409 | A | 20020321 | NO 2002-1409 | 20020321 |
| PRAI | DE 1999-19945982 | A | 19990924 | | |
| | WO 2000-EP9149 | W | 20000919 | | |
| IT | 269055-04-1 269055-15-4 269055-19-8 | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (controlled-release microparticle formulation for antiviral drugs) | | | | |
| RN | 269055-04-1 CAPLUS | | | | |
| CN | Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME) | | | | |



V. Balasubramanian


RN 269055-15-4 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-19-8 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



V. Balasubramanian

L5 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:335393 CAPLUS
DN 132:347578
TI Preparation of arylaminopyrimidines as inhibitors of HIV replication.
IN De Corte, Bart; De Jonge, Marc Rene; Heeres, Jan; Ho, Chih Yung; Janssen, Paul Adriaan Jan; Kavash, Robert W.; Koymans, Lucien Maria Henricus; Kukla, Michael Joseph; Ludovici, Donald William; Van Aken, Koen Jeanne Alfons
PA Janssen Pharmaceutica N.V., Belg.; et al.
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-------------------|----------|
| PI | WO 2000027825 | A1 | 20000518 | WO 1999-EP7417 | 19990924 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | AU 9962008 | A1 | 20000529 | AU 1999-62008 | 19990924 |
| | AU 762523 | B2 | 20030626 | | |
| | BR 9915552 | A | 20010814 | BR 1999-15552 | 19990924 |
| | TR 200101306 | T2 | 20011022 | TR 2001-200101306 | 19990924 |
| | EE 200100252 | A | 20021015 | EE 2001-252 | 19990924 |
| | NZ 511116 | A | 20030829 | NZ 1999-511116 | 19990924 |
| | EP 1002795 | A1 | 20000524 | EP 1999-203590 | 19991101 |
| | EP 1002795 | B1 | 20030305 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | EP 1270560 | A1 | 20030102 | EP 2002-18455 | 19991101 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| | AT 233740 | E | 20030315 | AT 1999-203590 | 19991101 |
| | US 2003114472 | A1 | 20030619 | US 1999-430966 | 19991101 |
| | PT 1002795 | T | 20030731 | PT 1999-203590 | 19991101 |
| | ES 2193664 | T3 | 20031101 | ES 1999-203590 | 19991101 |
| | HK 1025330 | A1 | 20030613 | HK 2000-104633 | 20000726 |
| | HR 2001000161 | A1 | 20020228 | HR 2001-161 | 20010307 |
| | NO 2001001696 | A | 20010404 | NO 2001-1696 | 20010404 |
| | BG 105418 | A | 20011130 | BG 2001-105418 | 20010406 |
| | ZA 2001003769 | A | 20020812 | ZA 2001-3769 | 20010509 |
| | US 2004039005 | A1 | 20040226 | US 2003-634682 | 20030805 |
| PRAI | US 1998-107792P | P | 19981110 | | |
| | US 1999-143962P | P | 19990715 | | |
| | US 1998-107792 | P | 19981110 | | |
| | US 1999-143962 | P | 19990715 | | |
| | WO 1999-EP7417 | W | 19990924 | | |
| | EP 1999-203590 | A3 | 19991101 | | |
| | US 1999-430966 | A1 | 19991101 | | |
| OS | MARPAT 132:347578 | | | | |
| IT | 269055-42-7P 269055-51-8P | | | | |


V. Balasubramanian

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of arylaminopyrimidines as inhibitors of HIV replication)


RN 269055-42-7 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-5-nitro-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-51-8 CAPLUS

CN Benzonitrile, 4-[[5-amino-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



IT 269055-04-1P 269055-05-2P 269055-14-3P
269055-15-4P 269055-18-7P 269055-19-8P
269055-26-7P 269055-28-9P 269055-32-5P
269055-44-9P 269055-48-3P 269055-49-4P
269055-50-7P 269055-58-5P 269055-59-6P
269055-60-9P 269055-61-0P 269055-62-1P
269055-63-2P 269055-78-9P 269055-79-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylaminopyrimidines as inhibitors of HIV replication)

V. Balasubramanian


RN 269055-04-1 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-05-2 CAPLUS

CN Benzonitrile, 4-[[5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-14-3 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-(methylamino)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-15-4 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-18-7 CAPLUS


CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-(ethylamino)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 269055-19-8 CAPLUS

CN Benzonitrile, 4-[[6-amino-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-26-7 CAPLUS

CN Benzonitrile, 4-[[5,6-dichloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-28-9 CAPLUS

CN Benzonitrile, 4-[[6-bromo-5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-32-5 CAPLUS

CN Acetamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)




RN 269055-44-9 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-methyl-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-48-3 CAPLUS


CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 269055-49-4 CAPLUS

CN Benzonitrile, 4-[[5-bromo-2-[(4-cyanophenyl)amino]-6-(methoxyamino)-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 269055-50-7 CAPLUS

CN Acetamide, N-[4-(4-cyano-2,6-dimethylphenoxy)-2-[(4-cyanophenyl)amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 269055-58-5 CAPLUS

CN Glycine, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 269055-59-6 CAPLUS


CN Formamide, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)- (9CI) (CA INDEX NAME)



RN 269055-60-9 CAPLUS


CN Carbamic acid, [5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl](4-cyanophenyl)-, ethyl ester (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 269055-61-0 CAPLUS

CN Glycine, N-[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-N-(4-cyanophenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 269055-62-1 CAPLUS


CN Propanoic acid, 2,2-dimethyl-, [[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl](4-cyanophenyl)amino]methyl ester (9CI) (CA INDEX NAME)



RN 269055-63-2 CAPLUS


CN Acetic acid, [2-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl](4-cyanophenyl)amino]-2-oxoethoxy]-, methyl ester (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 269055-78-9 CAPLUS

CN Benzonitrile, 4-[[5-amino-6-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 269055-79-0 CAPLUS

CN Benzonitrile, 4-[[5-amino-6-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



IT 269055-76-7


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of arylaminopyrimidines as inhibitors of HIV replication)

10/634,682

V. Balasubramanian

RN 269055-76-7 CAPLUS

CN Benzonitrile, 4-[[5-bromo-6-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:640840 CAPLUS

DN 131:257576

TI Preparation of HIV inhibiting pyrimidine derivatives

IN Andries, Koenraad Jozef Lodewijk Marcel; De Corte, Bart; De Jonge, Marc
 Rene; Heeres, Jan; Ho, Chih Yung; Janssen, Marcel August Constant;
 Janssen, Paul Adriaan Jan; Koymans, Lucien Maria Henricus; Kukla, Michael
 Joseph; Ludovici, Donald William; Van Aken, Koen Jeanne Alfons

PA Janssen Pharmaceutica N.V., Belg.; et al.

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 9950250 | A1 | 19991007 | WO 1999-EP2043 | 19990324 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 945442 | A1 | 19990929 | EP 1998-201587 | 19980514 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | CA 2324919 | AA | 19991007 | CA 1999-2324919 | 19990324 |
| | AU 9935996 | A1 | 19991018 | AU 1999-35996 | 19990324 |
| | AU 751573 | B2 | 20020822 | | |
| | BR 9909191 | A | 20001205 | BR 1999-9191 | 19990324 |
| | EE 200000532 | A | 20020215 | EE 2000-532 | 19990324 |
| | JP 3507917 | B2 | 20040315 | JP 2000-541155 | 19990324 |
| | BG 104738 | A | 20010430 | BG 2000-104738 | 20000830 |
| | HR 2000000620 | A1 | 20010630 | HR 2000-620 | 20000919 |
| | NO 2000004810 | A | 20000926 | NO 2000-4810 | 20000926 |
| PRAI | US 1998-79632P | P | 19980327 | | |
| | EP 1998-201587 | A | 19980514 | | |
| | EP 1998-203948 | A | 19981125 | | |
| | WO 1999-EP2043 | W | 19990324 | | |

OS MARPAT 131:257576


IT 244767-99-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of HIV inhibiting pyrimidine derivs.)

RN 244767-99-5 CAPLUS

CN Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl-
 (9CI) (CA INDEX NAME)

V. Balasubramanian



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

L5 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:631415 CAPLUS

DN 131:257575

TI Preparation of arylaminopyrimidines for treatment of human immunodeficiency virus infection.

IN Andries, Koenraad Jozef Lodewijk Marcel; De Corte, Bart; De Jonge, Marc Rene; Heeres, Jan; Ho, Chih Yung; Janssen, Marcel August Constant; Janssen, Paul Adriaan Jan; Koymans, Lucien Maria Henricus; Kukla, Michael Joseph; Ludovici, Donald William; Van Aken, Koen Jeanne Alfons

PA Janssen Pharmaceutica N.V., Belg.

SO Eur. Pat. Appl., 38 pp.


CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 3

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | EP 945443 | A1 | 19990929 | EP 1999-200918 | 19990324 |
| | EP 945443 | B1 | 20030212 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | EP 945442 | A1 | 19990929 | EP 1998-201587 | 19980514 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | EP 1245567 | A1 | 20021002 | EP 2002-14566 | 19990324 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| PRAI | US 1998-79632P | P | 19980327 | | |
| | EP 1998-201587 | A | 19980514 | | |
| | EP 1998-203948 | A | 19981125 | | |
| | EP 1999-200918 | A3 | 19990324 | | |
| OS | MARPAT 131:257575 | | | | |
| IT | 244767-99-5P | | | | |
| | RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | | |
| | (preparation of arylaminopyrimidines for treatment of HIV infection) | | | | |
| RN | 244767-99-5 CAPLUS | | | | |
| CN | Benzonitrile, 4-[[2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethyl- | | | | |
| | (9CI) (CA INDEX NAME) | | | | |



V. Balasubramanian

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

V. Balasubramanian

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

79.43

235.06

STN INTERNATIONAL LOGOFF AT 14:22:16 ON 17 AUG 2004